Clinical Trials Using Carfilzomib

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical trials are research studies that involve people. The clinical trials on this list are studying Carfilzomib. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-25 of 34
1 2 Next >

  • Bortezomib or Carfilzomib with Lenalidomide and Dexamethasone in Treating Patients with Newly Diagnosed Multiple Myeloma

    This randomized phase III trial studies bortezomib, lenalidomide, and dexamethasone to see how well they work compared to carfilzomib, lenalidomide, and dexamethasone in treating patients with newly diagnosed multiple myeloma. Bortezomib and carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may help the immune system kill abnormal blood cells or cancer cells. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether bortezomib, lenalidomide, and dexamethasone are more or less effective than carfilzomib, lenalidomide, and dexamethasone in treating patients with multiple myeloma
    Location: 815 locations

  • Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Treating Patients with Newly-Diagnosed Multiple Myeloma

    This phase II trial studies how well daratumumab, carfilzomib, lenalidomide, and dexamethasone work in treating patients with newly-diagnosed multiple myeloma. Monoclonal antibodies, such as daratumumab, may interfere with the ability of cancer cells to grow and spread. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving daratumumab, carfilzomib, lenalidomide, and dexamethasone may work better in treating patients with multiple myeloma.
    Location: 6 locations

  • Carfilzomib, Lenalidomide, and Dexamethasone in Treating Patients with Newly-Diagnosed Multiple Myeloma

    This phase I / II trial studies the side effects and best dose of carfilzomib when given together with lenalidomide and dexamethasone and to see how well they work in treating patients with newly-diagnosed multiple myeloma. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving carfilzomib together with lenalidomide and dexamethasone may work better in treating patients with newly-diagnosed multiple myeloma.
    Location: 6 locations

  • Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

    The purpose of the study is to determine the maximum tolerated dose and assess the safety, tolerability and activity of carfilzomib, alone and in combination with induction chemotherapy, in children with relapsed or refractory acute lymphoblastic leukemia (ALL).
    Location: 8 locations

  • Study of the Bruton's Tyrosine Kinase Inhibitor in Combination With Carfilzomib (Kyprolis™) in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma

    Phase 1 will be an open-label study. The dose escalation portion of the study is designed to establish the MTD of ibrutinib in combination with carfilzomib with or without dexamethasone. Phase 2b will be an open-label, multicenter study designed to evaluate the overall response rate when ibrutinib is administered in combination with carfilzomib and dexamethasone.
    Location: 6 locations

  • Carfilzomib in Treating Patients with Chronic Graft-Versus-Host Disease

    This pilot phase II trial studies how well carfilzomib works in treating patients with chronic graft-versus-host disease. Chronic graft-versus-host disease is a complication of a donor bone marrow or blood cell transplant, usually occurring more than three months after transplant, in which donor cells damage the host tissue. Carfilzomib may be an effective treatment for chronic graft-versus-host disease.
    Location: 5 locations

  • A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

    The purpose of this study is to evaluate the safety, tolerability, and dose regimen of daratumumab when administered in combination with various treatment regimens for the treatment of multiple myeloma.
    Location: 6 locations

  • An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

    This is a study of INCB052793 given to patients with advanced malignancies that will be conducted in three phases; Phase 1a (Monotherapy) and Phase 1b (Combination Therapy) and Phase 2 (Combination therapy of INCB052793 with azacitidine and itacitinib with azacitidine). Phase 1 will have two parts; a dose escalation (Part 1) and an expansion (Part 2).
    Location: 6 locations

  • Carfilzomib and Belinostat in Treating Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

    This phase I trial studies the side effects and best dose of carfilzomib and belinostat when given together in treating patients with non-Hodgkin lymphoma that has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Carfilzomib and belinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 4 locations

  • MDM2 Inhibitor AMG-232, Carfilzomib, Lenalidomide, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma

    This phase I trial studies the side effects and best dose of MDM2 inhibitor AMG-232 when given together with carfilzomib, lenalidomide, and dexamethasone in treating patient with multiple myeloma that has come back of has not responded to previous treatment. Drugs used in chemotherapy, such as MDM2 inhibitor AMG-232, carfilzomib, lenalidomide, and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: 3 locations

  • Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)

    A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in participants with relapsed or refractory MM and have received 1 to 3 prior lines of therapy.
    Location: 5 locations

  • A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

    This is a dose finding pilot study to evaluate the safety and determine the maximum tolerated dose of the combination of carfilzomib and pomalidomide with dexamethasone (CPD) in patients with relapsed or refractory multiple myeloma followed by a phase II expansion at the MTD to evaluate efficacy.
    Location: 3 locations

  • Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and / or Refractory Multiple Myeloma.

    Compare carfizomib, dexamethasone, and daratumumab (KdD) to Carfilzomib and dexamethasone (Kd) in terms of progression free survival (PFS) in patients with multiple myeloma who have relapsed after 1 to 3 prior therapies.
    Location: 2 locations

  • Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients

    The purpose of this study is to determine a well-tolerated dose of Carfilzomib in combination with Irinotecan (Phase 1b portion of the study) in subjects with relapsed small and non-small cell lung cancer or other irinotecan-sensitive cancers and to assess the 6 month survival of relapsed small cell lung cancer patients treated with this combination therapy. **The Phase 1b portion of the study is now complete**. Phase 2 portion of the study. The safest, maximally tolerated dose established as established in Phase 1 for Phase 2 is as follows -- Carfilzomib will be provided at 20 / 36 mg / m2 with Irinotecan dosed at 125 mg / m2. The purpose of the Phase 2 portion of the study is to assess 6 month survival of relapsed small cell lung cancer ins subjects treated with this combination therapy.
    Location: 2 locations

  • Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma

    This phase Ib / II trial studies the side effects and best dose of carfilzomib and to see how well it works when given together with pomalidomide and dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement or does not respond to treatment. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Pomalidomide may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving carfilzomib together with pomalidomide and dexamethasone may kill more cancer cells.
    Location: 4 locations

  • Carfilzomib, Lenalidomide, and Dexamethasone in Treating Patients with Smoldering Multiple Myeloma

    This pilot phase II trial studies carfilzomib, lenalidomide, and dexamethasone in treating patients with smoldering multiple myeloma. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving carfilzomib, lenalidomide, and dexamethasone may be an effective treatment for multiple myeloma.
    Location: 2 locations

  • Elotuzumab, Carfilzomib, Lenalidomide, and Low Dose Dexamethasone in Treating Patients with Newly Diagnosed Multiple Myeloma

    This phase II clinical trial studies how well elotuzumab, carfilzomib, lenalidomide, and low dose dexamethasone work in treating patients with newly diagnosed multiple myeloma. Monoclonal antibodies, such as elotuzumab, may block tumor growth in different ways by targeting certain cells. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving elotuzumab, carfilzomib, lenalidomide, and dexamethasone may work better in treating patients with multiple myeloma.
    Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois

  • Carfilzomib and PI3K-delta Inhibitor TGR-1202 in Treating Patients with Relapsed or Refractory Lymphoma

    This phase I / II trial studies the best dose and side effects of carfilzomib and PI3K-delta inhibitor TGR-1202 and how well they work in treating patients with lymphoma that has come back or does not respond to treatment. Carfilzomib and PI3K-delta inhibitor TGR-1202 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
    Location: Columbia University / Herbert Irving Cancer Center, New York, New York

  • Lenalidomide with or without Carfilzomib and Dexamethasone in Treating Patients with Multiple Myeloma after Stem-Cell Transplant

    This randomized phase III trial studies how well lenalidomide with or without carfilzomib and dexamethasone works in treating patients with multiple myeloma after stem-cell transplant. Lenalidomide may help the immune system kill abnormal blood cells or cancer cells. It may also prevent the growth of new blood vessels that tumors need to grow. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Dexamethasone is a drug used to reduce inflammation and lower the body’s immune response. Giving lenalidomide together with carfilzomib and dexamethasone may be an effective treatment for multiple myeloma.
    Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois

  • SAR650984 and Carfilzomib in Treating Patients with Relapsed or Refractory Multiple Myeloma

    This phase Ib trial studies the side effects and best dose of anti-cluster of differentiation (CD)38 monoclonal antibody SAR650984 (SAR650984) when given together with carfilzomib in treating patients with multiple myeloma that has returned after a period of improvement or has not respond to previous treatment. Monoclonal antibodies, such as SAR650984, may block cancer growth in different ways by targeting certain cells. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving SAR650984 together with carfilzomib may be a better treatment for patients with multiple myeloma.
    Location: UCSF Medical Center-Mount Zion, San Francisco, California

  • Carfilzomib and Hyper-CVAD in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma

    This phase I trial studies the side effects and best dose of carfilzomib when given together with the hyperfractionated (hyper)-cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, and dexamethasone (CVAD) chemotherapy regimen in treating patients with newly diagnosed acute lymphoblastic leukemia or lymphoma. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving carfilzomib with combination chemotherapy may kill more cancer cells.
    Location: University of California Davis Comprehensive Cancer Center, Sacramento, California

  • Carfilzomib, Bendamustine Hydrochloride, and Rituximab in Treating Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

    This phase Ib trial studies the side effects and best dose of carfilzomib when given together with bendamustine hydrochloride and rituximab in treating patients with B-cell non-Hodgkin lymphoma that has returned after a period of improvement or has not responded to previous treatment. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as rituximab, may block cancer growth in different ways by targeting certain cells. Giving carfilzomib together with bendamustine hydrochloride and rituximab may be a better treatment for B-cell non-Hodgkin lymphoma.
    Location: UCSF Medical Center-Mount Zion, San Francisco, California

  • Wild-type Reovirus in Combination with Carfilzomib and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma

    This pilot phase I clinical trial studies the side effects and best dose of wild-type reovirus when combined with carfilzomib and dexamethasone in treating patients with multiple myeloma that has come back following treatment or does not respond to treatment. Drugs used in chemotherapy, such as dexamethasone and carfilzomib, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. A virus called wild-type reovirus may be able to kill cancer cells without damaging normal cells and seems to work best when given with chemotherapy. Giving wild-type reovirus with chemotherapy may be a more effective treatment than chemotherapy alone.
    Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio

  • A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023 / KEYNOTE-023)

    This is a study of pembrolizumab (MK-3475) in combination with lenalidomide and low-dose dexamethasone in participants with refractory or relapsed and refractory Multiple Myeloma (rrMM), and in combination with carfilzomib and low-dose dexamethasone in participants with relapsed or refractory Multiple Myeloma (rMM). This study is being done to find the maximum tolerated dose (MTD) / maximum administered dose (MAD) and recommended Phase 2 dose (RP2D), and to evaluate the safety and tolerability of pembrolizumab when given in combination with standard of care (SOC) treatments in participants with rrMM or rMM. Preliminary efficacy data will also be assessed. The primary study hypothesis is that these combinations are sufficiently well tolerated to permit further clinical investigation.
    Location: 2 locations

  • Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy

    This phase II trial studies how well carfilzomib works in treating patients with multiple myeloma in first relapse or refractory to first-line therapy. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
    Location: Indiana University / Melvin and Bren Simon Cancer Center, Indianapolis, Indiana


1 2 Next >